CRNX

Crinetics Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

30.990

+0.58(1.907%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

31.500

Open

30.410

VWAP

30.61

Vol

737.32K

Mkt Cap

2.90B

Low

29.720

Amount

22.57M

EV/EBITDA(TTM)

Total Shares

78.86M

1.63B

EV/OCF(TTM)

P/S(TTM)

3.50K

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q1

485.79K

+21.75%

100.00K

-84.38%

Estimates Revision

The market is revising Downward the revenue expectations for Crinetics Pharmaceuticals, Inc. (CRNX) for FY2025, with the revenue forecasts being adjusted by -17.74% over the past three months. During the same period, the stock price has changed by -6.40%.

Revenue Estimates for FY2025

Revise Downward

-17.74%

In Past 3 Month

Stock Price

Go Down

-6.40%

In Past 3 Month

9 Analyst Rating

149.27% Upside

Wall Street analysts forecast CRNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRNX is 77.25 USD with a low forecast of 60.00 USD and a high forecast of 97.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

149.27% Upside

Current: 30.990

Low

60.00

Averages

77.25

High

97.00

149.27% Upside

Current: 30.990

Low

60.00

Averages

77.25

High

97.00

Goldman Sachs

Richard Law

Neutral

initiated

$36

2025-07-10

Reason

Goldman Sachs

Richard Law

Price Target

$36

2025-07-10

initiated

Neutral

Reason

Goldman Sachs analyst Richard Law initiated coverage of Crinetics with a Neutral rating and $36 price target. The sees the stock's near-term value being meaningfully influenced by uncertainties of paltusotine's and Crenessity's launch performances given Crinetics' lack of other meaningful pipeline catalysts.

Stifel

Alex Thompson

Strong Buy

Initiates

$60

2025-03-25

Reason

Stifel

Alex Thompson

Price Target

$60

2025-03-25

Initiates

Strong Buy

Reason

Citizens Capital Markets

Jonathan Wolleben

Buy

Maintains

$92 → $91

2025-02-28

Reason

Citizens Capital Markets

Jonathan Wolleben

Price Target

$92 → $91

2025-02-28

Maintains

Buy

Reason

Wolfe Research

Andy Chen

Hold

Initiates

n/a

2025-02-04

Reason

Wolfe Research

Andy Chen

Price Target

n/a

2025-02-04

Initiates

Hold

Reason

Jefferies

Dennis Ding

Hold

Strong Buy

Upgrades

$55

2025-01-22

Reason

Jefferies

Dennis Ding

Price Target

$55

2025-01-22

Upgrades

Hold

Strong Buy

Reason

HC Wainwright & Co.

Douglas Tsao

Strong Buy

Reiterates

$81

2025-01-13

Reason

HC Wainwright & Co.

Douglas Tsao

Price Target

$81

2025-01-13

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Crinetics Pharmaceuticals Inc (CRNX.O) is -6.60, compared to its 5-year average forward P/E of -8.04. For a more detailed relative valuation and DCF analysis to assess Crinetics Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.04

Current PE

-6.60

Overvalued PE

-5.18

Undervalued PE

-10.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.42

Current EV/EBITDA

-3.68

Overvalued EV/EBITDA

-2.47

Undervalued EV/EBITDA

-8.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

930.68

Current PS

249.91

Overvalued PS

2191.28

Undervalued PS

-329.92